Literature DB >> 223577

Quantification of human plasma inorganic pyrophosphate. I. Normal values in osteoarthritis and calcium pyrophosphate dihydrate crystal deposition disease.

L M Ryan, F Kozin, D J McCarty.   

Abstract

The methodologic variables of the UDPG pyrophosphorylase method for analysis of inorganic pyrophosphate (PPi) levels in biologic fluids are described. Use of a tourniquet in collection of blood specimens elevated plasma PPi levels from 35% to 55% above control values and may explain the differences in published normal values. The sodium pyrophosphate decahydrate used to prepare the standard solution lost 8 waters of hydration after dessication, which could result in the calculation of spuriously elevated PPi levels. Normal plasma PPi concentration was 2.18 muM with a range (95% confidence limits) of 0.58-3.78 muM. Comparison of plasma PPi in normal subjects, patients with primary osteoarthritis, and patients with calcium pyrophosphate dihydrate deposition disease revealed no significant intergroup differences.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 223577     DOI: 10.1002/art.1780220812

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  12 in total

1.  Understanding inorganic pyrophosphate metabolism: toward prevention of calcium pyrophosphate dihydrate crystal deposition.

Authors:  L M Ryan; D J McCarty
Journal:  Ann Rheum Dis       Date:  1995-12       Impact factor: 19.103

2.  Proceedings of a symposium on crystal-related arthropathies. 22 October and 23 October, 1982, Bristol Polytechnic, Bristol.

Authors: 
Journal:  Ann Rheum Dis       Date:  1983-08       Impact factor: 19.103

Review 3.  Crystals, joints, and consternation.

Authors:  D McCarty
Journal:  Ann Rheum Dis       Date:  1983-06       Impact factor: 19.103

Review 4.  Pathogenesis of chondrocalcinosis and pseudogout. Metabolism of inorganic pyrophosphate and production of calcium pyrophosphate dihydrate crystals.

Authors:  A Caswell; D F Guilland-Cumming; P R Hearn; M K McGuire; R G Russell
Journal:  Ann Rheum Dis       Date:  1983-08       Impact factor: 19.103

5.  Biochemical and genetic analysis of ANK in arthritis and bone disease.

Authors:  Kyle A Gurley; Richard J Reimer; David M Kingsley
Journal:  Am J Hum Genet       Date:  2006-10-16       Impact factor: 11.025

6.  Heightened avidity for trisodium pyrophosphate in mice lacking Tas1r3.

Authors:  Michael G Tordoff; Tiffany R Aleman; Stuart A McCaughey
Journal:  Chem Senses       Date:  2014-12-01       Impact factor: 3.160

7.  Pyrophosphohydrolase activity and inorganic pyrophosphate content of cultured human skin fibroblasts. Elevated levels in some patients with calcium pyrophosphate dihydrate deposition disease.

Authors:  L M Ryan; R L Wortmann; B Karas; M P Lynch; D J McCarty
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

8.  Purine receptors modulate chondrocyte extracellular inorganic pyrophosphate production.

Authors:  A K Rosenthal; D Hempel; I V Kurup; I Masuda; L M Ryan
Journal:  Osteoarthritis Cartilage       Date:  2010-08-13       Impact factor: 6.576

9.  Fibrositis: misnomer for a common rheumatic disorder.

Authors:  R M Bennett
Journal:  West J Med       Date:  1981-05

10.  Resistance to excision determines efficiency of hepatitis C virus RNA-dependent RNA polymerase inhibition by nucleotide analogs.

Authors:  Brian Villalba; Jiawen Li; Kenneth A Johnson
Journal:  J Biol Chem       Date:  2020-05-26       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.